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Abstract
Cerebral ischemia triggers acute inflammation, which has been associated with an increase in brain damage. The
mechanisms that regulate the inflammatory response after cerebral ischemia are multifaceted. An important
component of this response is the activation of the innate immune system. However, details of the role of the innate
immune system within the complex array of mechanisms in cerebral ischemia remain unclear. There have been recent
great strides in our understanding of the innate immune system, particularly in regard to the signaling mechanisms of
Toll-like receptors (TLRs), whose primary role is the initial activation of immune cell responses. So far, few studies have
examined the role of TLRs in cerebral ischemia. However, work with experimental models of ischemia suggests that
TLRs are involved in the enhancement of cell damage following ischemia, and their absence is associated with lower
infarct volumes. It may be possible that therapeutic targets could be designed to modulate activities of the innate
immune system that would attenuate cerebral brain damage. Ischemic tolerance is a protective mechanism induced by
a variety of preconditioning stimuli. Interpreting the molecular mechanism of ischemic tolerance will open investigative
avenues into the treatment of cerebral ischemia. In this review, we discuss the critical role of TLRs in mediating cerebral
ischemic injury. We also summarize evidence demonstrating that cerebral preconditioning downregulates pro-
inflammatory TLR signaling, thus reducing the inflammation that exacerbates ischemic brain injury.
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Introduction
Cerebral ischemia, the most common cerebrovascular
disease, is one of the leading causes of morbidity and
mortality around the world. However, many details of
the pathogenesis of cerebral ischemia are not fully
known. Cerebral ischemia is a condition of complex
pathology that includes several inflammatory events,
such as aggregation of inflammatory cells and upregula-
tion of cytokines. Particularly, accumulating evidence
suggests that Toll-like receptors (TLRs) are important
mediators of cerebral ischemic injury. Therefore, under-
standing TLRs and their relationship to cerebrovascular
disease is becoming increasingly important to basic and
clinical scientists.
TLRs are key receptors in the mammalian innate
immune response to infectious microorganisms, but are
also activated by host-derived molecules. The associa-
tion between TLRs and the activation of a variety of
downstream inflammatory cascades has been established
in cerebral ischemia, as well as an involvement in
inflammatory injury. Additionally, many diverse neuro-
protective networks may redirect TLR signaling as one
mechanism of endogenous protection.
The purpose of this review is to (1) summarize cur-
rent knowledge on TLR signaling; (2) examine the evi-
dence implicating TLRs in cerebral ischemia injury, (3)
outline known mechanisms of TLR-mediated neuronal
damage, and (4) summarize the information on other
molecules involved in TLR signaling. The latter may
help identify potential clinical targets for preventing
TLR-mediated cerebral ischemic injury.
The innate immune response in the central nervous
system (CNS)
It was initially believed that innate immunity was an
immunological program engaged by peripheral organs
to maintain homeostasis after nonspecific stress and
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immunity is a highly organized response that also takes
place in the CNS [1,2]. In fact, the CNS shows a well-
organized innate immune reaction in response to sys-
temic bacterial infection and cerebral injury [1,3].
The innate immune response in the CNS is character-
ized by the expression of various immunological pro-
teins in the circumventricular organs as well as other
structures that are not subject to the blood-brain barrier
(BBB). This expression of immunological proteins
extends progressively to affect microglia across the brain
parenchyma and may lead to the onset of an adaptive
immune response. The innate immune system of the
CNS maintains a critical balance between the protective
and the potentially harmful effects of its activation fol-
lowing acute brain injury, the so-called “double-edged
sword” effect [4]. The balance between the destructive
and protective effects of the innate immune response
must be precisely regulated to promote conditions that
support brain repair and maintain tissue homeostasis
[5].
T h ei n n a t ei m m u n er e s p o n s eo ft h eC N Sr e l i e su p o n
its resident cells’ (neurons and glia) phagocytic and sca-
venger receptors, which are capable of distinguishing
“self” from “nonself “ [6]. Microglia, the resident
immune cells of the CNS, are sensitive sensors of events
occurring within their environment and provide the first
line of defense against invading microbes [6]. Microglia
respond to CNS injuries with increased proliferation,
motility, phagocytic activity, and the release of cytokines
and reactive oxygen species [7]. Upon recognition of
pathogens, activated microglia accumulate at sites of tis-
sue damage and express proinflammatory cytokines,
adhesion molecules, and free radicals [2,8]. Activation of
microglia also results in increased expression of major
histocompatibility complex and co-stimulatory mole-
cules, and stimulates responses in CD4 and CD8 T
helper cells. Therefore microglia serve as important anti-
gen-presenting cells of the CNS [7].
CNS injuries also trigger phagocytic and cytotoxic
functions in microglia. When activated, microglia upre-
gulate opsonic receptors. These include both comple-
ment (CR1, CR3, CR4) and Fcg receptors (I, II, III),
which enhance phagocytic activity by binding to com-
plement components and immunoglobulin fragments,
respectively [7]. In contrast, the cytotoxic functions of
microglia are carried out through the release of superox-
ide radicals and proinflammatory mediators into the
microenvironment in response to pathogens and cyto-
kine stimulation [7]. It has also been noted that micro-
glia are activated in some diseases of the CNS, they are
among the first cells found at the site of tissue injury
and infection, and recruit other immune cells [2].
Therefore, microglia play a central role in innate
immunity, recognizing both pathogen- and damage-
associated molecular patterns, and have been implicated
in a range of neuronal inflammatory processes.
Toll-like receptors (TLRs) in CNS
In the past few years, it has become evident that the
innate immune system, and in particular pattern recog-
nition receptors, have evolved to detect components of
foreign pathogens. These components are referred to as
pathogen-associated molecular patterns (PAMPs), and
include Toll-like receptors (TLRs) which play a major
role in both infectious and non-infectious CNS
diseases [9-11].
TLRs are type I transmembrane proteins with ectodo-
mains containing leucine-rich repeats. These repeats
mediate the recognition of PAMPs, transmembrane
domains, and intracellular Toll-interleukin 1 (IL-1)
receptor (TIR) domains required for downstream signal
t r a n s d u c t i o n[ 1 1 ] .S of a r ,1 0a n d1 2f u n c t i o n a lT L R s
have been identified in humans and mice, respectively,
with TLR1-TLR9 being conserved in both species.
Mouse TLR10 is not functional because of a retrovirus
insertion, and TLR11, TLR12 and TLR13 have been lost
from the human genome [10].
Studies of mice deficient in each TLR have demon-
strated that each TLR has a distinct function in terms of
PAMP recognition and immune responses [10]. PAMPs
recognized by TLRs include lipids, lipoproteins, proteins
and nucleic acids derived from a wide range of microbes
such as bacteria, viruses, parasites and fungi [10]. The
recognition of PAMPs by TLRs occurs in various cellu-
lar compartments, including the plasma membrane,
endosomes, lysosomes and endolysosomes [10]. TLRs
detect a wide range of PAMPs that are found on bac-
teria, viruses, fungi, and parasites. These include pro-
teins, lipids, and nucleic acids. For example, TLRs
recognize the bacterial cell wall components peptidogly-
can (TLR2) and lipopolysaccharide (TLR4), as well as
dsRNA (TLR3), ssRNA (TLR7), and non-methylated
cytosine-guanosine (CpG) DNA (TLR9) [9,10].
TLR expression in the CNS
Constitutive expression of TLRs within the brain occurs
in microglia and astrocytes, and is largely restricted to
the circumventricular organs and meninges areas with
direct access to the circulation [12]. In general, TLRs
are located on antigen-presenting cells such as B cells,
dendritic cells, monocytes, macrophages, and microglia
in the CNS. In addition, these receptors can be
expressed by the endothelium and by cells within the
brain parenchyma such as astrocytes, oligodendrocytes,
and neurons [13,14]. For example, human microglia
express TLRs 1-9 and generate cytokine profiles tailored
by the specific TLR stimulated [13,15]. Similarly, human
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TLR3 expression [15].
Oligodendrocytes and endothelial cells express a rela-
tively limited repertoire of TLRs. Oligodendrocytes
express TLRs 2 and 3, while cerebral endothelial cells
constitutively express TLRs 2, 4, and 9 and increase
their expression of these TLRs in response to stressful
stimuli [15]. Human neurons express TLRs 2, 3, 4, 8,
and 9 [15].
Notably, microglia and astrocytes respond differently
to specific TLR engagement, reflective of their distinct
roles in the brain. Microglia initiate robust cytokine and
chemokine responses upon stimulation of TLR2 (TNF-
a, IL-6, IL-10), TLR3 (TNF-a, IL-6, IL-10, IL-12,
CXCL-10, IFN-b), and TLR4 (TNF-a, IL-6, IL-10,
CXCL-10, IFN-b), yet astrocytes initiate only minor IL-6
responses to all but TLR3 stimulation [12].
TLR signaling
The TLRs signal through common intracellular path-
ways leading to transcription factor activation and the
generation of cytokines and chemokines (Figure 1) [16].
TLRs recruit five adaptors including myeloid differentia-
t i o np r i m a r yr e s p o n s eg e n e8 8( M y D 8 8 ) ,M y D 8 8a d a p -
tor-like protein (MAL), TIR-domain-containing adaptor
protein inducing interferon (IFN)-b-mediated transcrip-
tion factor (TRIF), TRIF-related adaptor molecule
(TRAM), and sterile a- and armadillo motif-containing
protein (SARM) [17]. TLRs interact with their respective
adaptors via the homologous binding of their unique
TIR domains present in both the receptors and the
adaptor molecules.
Based on the specific adaptors recruited, TLR signal-
ing can take either the MyD88-dependent or MyD88-
independent pathways. In general, each TLR family
member, with the exception of TLR3, signals through
the MyD88-dependent pathway, initiated by the MyD88
adaptor protein. Recruitment of MyD88 to the activated
receptor initiates formation of the IL-1 receptor asso-
ciated kinase (IRAK) complex resulting in phosphoryla-
tion of IKKa/b, activation of the transcription factors
NF-B, interferon-b promoter-binding protein (IRF)1,
and IRF7, and generation of the pro-inflammatory cyto-
kines IL-6 and TNF-a, among others [18].
TLR3, on the other hand, signals through the MyD88-
independent pathway, initiated by the TRIF adaptor
molecule. Recruitment of TRIF to the receptor initiates
phosphorylation of IKKε, which activates the transcrip-
tion factors IRF3 and IRF7, and generates anti-viral
molecules such as IFN-b.O ft h eT L R s ,o n l yT L R 4c a n
utilize either of these pathways [18].
It is noteworthy that MyD88 is also recruited to the
endosomal receptors TLR7 and TLR9, again enlisting
members of the IRAK family [11]. Due to the
endosomal location of the complex, the phosphorylated
IRAKs are able to bind TRAF3 in addition to TRAF6.
Activation of TRAF3 leads to phosphorylation, dimeriza-
tion, and nuclear localization of the transcription factors
IRF3, IRF5, and IRF7 with resultant type I IFN produc-
tion. Hence these endosomal TLRs are capable of signal-
ing to NF-B, AP-1 and IRFs, resulting in a diverse
genomic response [11].
TLR ligands
TLRs are largely divided into two subgroups depending
on their cellular localization and respective PAMP
ligands. One group is composed of the TLRs 1, 2, 4, 5,
6 and 11, which are expressed on cell surfaces and
recognize mainly microbial membrane components such
as lipids, lipoproteins, and proteins. The other group
consists of TLRs 3, 7, 8 and 9, which are expressed
exclusively in intracellular vesicles such as the endoplas-
mic reticulum (ER), endosomes, lysosomes and endoly-
sosomes, where they recognize microbial nucleic acids
[15] (Table 1).
In detail, TLR4 predominantly recognizes lipopolysac-
charide (LPS) from gram-negative bacteria. TLR2
dimerizes with TLR1 to recognize triacylated lipopep-
tides from bacteria. TLR2 also dimerizes with TLR6 and
responds to a variety of PAMPs including peptidogly-
cans, diacylated lipopeptides such as Pam2CSK4, LPSs
of gram-positive bacteria, fungal zymosan, and myco-
plasma lipopeptides. TLR5 is mainly expressed in the
intestine where it senses bacterial flagellin protein.
TLR11 possibly recognizes an unknown ligand from an
u r o p a t h o g e n i cb a c t e r i aa n dap r o f i l i n g - l i k em o l e c u l eo f
the protozoan Toxoplasma gondii. TLR3 is activated in
response to double-stranded RNA (dsRNA) of viral ori-
gin. Human TLR8 and its murine orthologue, TLR7,
recognize imidazoquinoline and viral ssRNA. TLR9
recognizes unmethylated CpG dinucleotides found in
bacteria as well as viral genomes.
TLRs also detect some endogenous ligands, including
fibrinogen, heat shock proteins (HSP; HSP60, and
HSP70 for TLR2 and 4), saturated fatty acids (TLR 2
and 4), mRNA (TLR3), hyaluronan fragments, heparan
sulfate, fibronectin extra domain A, lung surfactant pro-
tein A, or high mobility group box 1 protein (HMGB1;
TLR4). The known endogenous ligands of TLRs are
either molecules released from damaged cells or extra-
cellular matrix breakdown products. In this way, innate
immune inflammatory responses may be activated with-
out the presence of invading pathogens but merely as a
result of tissue damage.
TLRs and ligands in cerebral ischemic damage
Accumulating evidence shows that ischemic injury and
inflammation account for the pathogenic progression of
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responses that result in organ damage after ischemic
injury has been studied extensively. The ability of TLRs
to mediate inflammatory responses in immune cells sug-
gests their involvement in these and in ischemia-induced
brain damage.
T h ei n f l a m m a t o r yr e s p o n s et oc e r e b r a li s c h e m i ai s
initiated by the detection of injury-associated molecules
by local cells such as microglia and astrocytes. The
response is further promoted by infiltrating neutrophils
and macrophages, resulting in the production of inflam-
matory cytokines, proteolytic enzymes, and other
Figure 1 Toll-like receptor (TLR) signaling. TLRs are transmembrane proteins with a large extra-cellular domain containing a cytoplasmic Toll/
IL-1 receptor (TIR) domain. All TLR family members, except TLR3, signal through the myeloid differentiation primary-response gene 88 (MyD88)
to recruit downstream interleukin (IL)-1 receptor-associated kinases (IRAKs) and tumor necrosis factor (TNF)-receptor associated factor 6 (TRAF6).
In TLR2 and TLR4 signaling, MyD88 adaptor-like protein (MAL) is required for recruiting MyD88 to their receptors, whereas in others such as
TLR5, TLR7, TLR9, and TLR11, MAL is not required. TLR1 and TLR2 or TLR2 and TLR6 form heterodimers that signal through MAL/MyD88. TLR3
signals through the adaptor TIR-domain-containing adaptor protein inducing interferon (IFN)-b-mediated transcription-factor (Trif), which recruits
and activates TNF receptor-associated factor-family member-associated NF-B activator-binding kinase 1 (TBK1). In addition to the MAL/MyD88-
dependent pathway, TLR4 can also signal through a MyD88-independent pathway that activates TBK1 via a Trif-related adaptor molecule
(TRAM)-Trif-dependent mechanism. TLR5, TLR7/8, TLR9, and TLR11 use only MyD88 as its signaling adaptor. These kinases ultimately activate
transcription factors such as nuclear factor-B (NF-B) and IFN regulatory factors (IRFs), which result in production of various cytokines such as
TNF, IL, and IFNs.
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dence that TLRs and their ligands play a crucial role in
cerebral ischemic injuries and neuronal cell death
[19-30]. However, the complex array of mechanisms and
the precise role of TLRs in mediating neuronal damage
remain to be fully elucidated.
The role of TLR4 in cerebral ischemia
TLR4 plays an important role in the innate immunity of
the CNS [31]. Numerous studies demonstrate that TLR4
participates in cerebral injury upon ischemic stroke. Sev-
eral studies confirm that cerebral ischemia results in the
upregulation of TLR4 mRNA in neurons as early as one
hour after initiation of ischemia in vivo [19,32].
Importantly, cortical neuronal cultures from TLR4-
deficient mice show increased survival after glucose
deprivation [32]. Mice lacking TLR4 exhibit reduced
infarct size compared with wild-type mice after cerebral
ischemic injury [23,24,32-34]. TLR4-mutant mice sub-
jected to middle cerebral artery occlusion (MCAO) or
animals suffering global cerebral ischemia exhibit
improved neurological behavior and reduced edema, as
well as reduced levels of secretion of proinflammatory
c y t o k i n e ss u c ha sT N F - a and IL-6 [23,24,33]. In addi-
tion, mice lacking TLR4 have reduced expression of
inducible nitric oxide synthase (iNOS), cyclooxygenase 2
(COX2), and IFN-g [24,33].
Likewise, a TLR4 mutation confers protection against
MCAO [34]. Moreover, after MCAO, loss of TLR4 func-
tion is associated with reduced expression of p38 and
Erk1/2 in damaged neurons, implicating TLR4 in
MCAO injury [23,24,32,34].
Taken together, these studies indicate that TLR4 sig-
naling modulates the severity of ischemia-induced neu-
ronal damage.
The role of TLR2 in cerebral ischemia
TLR2 has been shown to play a role in cerebral
ischemic damage [32,35-38]. TLR2 mRNA was upregu-
lated in the brain of mice during cerebral ischemia and
expressed in lesion-associated microglia [32]. TLR2-defi-
cient mice displayed less CNS injury compared with
wild-type mice in a model of focal cerebral ischemia
[32]. Neurons from TLR2-knockout mice were protected
against cell death induced bye n e r g yd e p r i v a t i o n[ 3 5 ] .
And, the amount of brain damage and neurological
Table 1 Exogenous and endogenous TLR ligands.
TLRs Major cell types Exogenous ligands Endogenous ligands
TLR1 Myeloid cells
T, B and NK cells, microglia,
astrocytes
Bacterial triacyl-lipopeptide
TLR2 Myeloid cells, T cells, microglia,
astrocytes, oligodendrocytes,
neurons
Lipoproteins/lipopeptides, lipoteichoic
acid, lipoarabinomannan,
peptidoglycan,
glycoinositolphospholipids, glycolipids,
porins, zymosan, atypical
lipopolysaccharide
Heat-shock proteins 60 and 70, Gp96,
Saturated fatty acids
TLR3 Epithelial cells, dendritic cells,
microglia, astrocytes,
oligodendrocytes, neurons
Double-stranded RNA mRNA
TLR4 Myeloid cells, microglia,
astrocytes, neurons
Lipopolysaccharide, paclitaxel,
respiratory syncytial virus fusion
protein, mouse mammary tumor virus
envelope proteins
Heat-shock proteins 60 and 70,
Gp96, Type III repeat extra domain A of fibronectin,
oligosaccharides of hyaluronic acid, polysaccharide fragments of
heparin sulfate, fibrinogen, high mobility group box 1, surfactant
protein-A, b-defensin 2
TLR5 Myeloid cells, epithelial cells,
microglia, astrocytes
Flagellin
TLR6 Myeloid cells, dendritic cells,
microglia, astrocytes
Phenol-soluble modulin, diacyl
lipopeptides, lipoteichoic acid,
zymosan
TLR7 B cells, dendritic cells, microglia,
astrocytes
Imidazoquinoline, loxoribine,
bropirimine,
Single-stranded RNA
TLR8 Myeloid cells, microglia,
astrocytes, neurons
Single-stranded RNA
TLR9 Epithelial and B cells, dendritic
cells, microglia, astrocyte, neuron
Unmethylated CpG DNA Chromatin-IgG complexes
TLR10 B cells, dendritic cells Unknown, may interact with TLR2
TLR11 Myeloid cells, uroepithelial cells Uropathogenic E. coli
(Marsh et al., 2009b[13];Takeda and Akira, 2004[18]; Cristofaro and Opal, 2006[67]; Guo and Schluesener, 2007[68]; Tsan and Gao, 2004[69];)
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mice deficient in TLR2 compared with wild-type control
mice [35]. Moreover, TLR2 has been proved to be the
most significantly upregulated TLR in the ipsilateral
brain hemisphere [36].
TLR2 protein was expressed mainly in microglia in
post-ischemic brain tissue, but also in selected endothe-
lial cells, neurons, and astrocytes; TLR2-related genes
with pro-inflammatory and pro-apoptotic capabilities
were also induced. Two days after a one hour induction
of transient focal cerebral ischemia, the infarct volume
in TLR2-deficient mice was significantly smaller com-
pared to wild-type mice. Therefore, TLR2 upregulation
and TLR2 signaling are important events in focal cere-
bral ischemia and contribute to ischemic damage [36].
Interestingly, one recent study demonstrated that
inflammatory signaling of the TLR2 heterodimer TLR2/
1 in the post-ischemic brain requires the scavenger
receptor CD36 [37]. In CD36-null mice, activators of
TLR2/1 did not trigger inflammatory gene expression
and did not exacerbate ischemic injury. The link
between CD36 and TLR2/1 was specific for brain
inflammation because CD36 is required for TLR2/6
(another TLR2 heterodimer) signaling. These findings
raise the possibility that the TLR2/1-CD36 complex is a
critical sensor of danger signals produced by cerebral
ischemia [37].
A more recent study demonstrated that TLR2 med-
iates leukocyte and microglial infiltration and neuronal
death, which can be attenuated by TLR2 inhibition [38].
The TLR2 inhibition in vivo improves neuronal survival
and may represent a future stroke therapy [38].
However, studies have demonstrated that TLR2 and
TLR4 appear to play opposing roles in cerebral ischemia
[35,36,39]. Ziegler et al compared the response of
TLR2
-/- and TLR4
-/- mice to cerebral ischemia [36].
They found that TLR2
-/- mice had a smaller infarct size.
However, Hua et al. demonstrated that brain infarct size
was significantly less in TLR4
-/- mice but was increased
in TLR2
-/- mice [39]. The difference between this study
and that of Ziegler et al. may be because Zeigler et al.
occluded the middle cerebral artery, whereas Hua et al.
occluded the common and internal carotid arteries.
Alternatively, the difference in results may be a conse-
quence of the differing genetic backgrounds of the
transgenic mice.
The role of HMGB1 in cerebral ischemia
The TLR endogenous ligand HMGB1 has been very
recently implicated in the mechanism of ischemic brain
damage [21,25-28,40,41]. Three novel studies in particu-
lar have indicated that HMGB1 plays a pivotal role in
ischemic brain injury. Firstly, short hairpin RNA
(shRNA)-mediated HMGB1 downregulation in the post-
ischemic brain suppressed infarct size [25]. Reducing
HMGB1 expression by shRNA attenuated ischemia-
dependent microglia activation and induction of inflam-
matory cytokines and enzymes (TNF-a,I L - 1 b and
iNOS) in the ischemic brain [25].
More recently, treatment with neutralizing anti-
HMGB1 monoclonal antibody (mAb) remarkably ame-
liorated brain infarction induced by a 2-hour occlusion
of the middle cerebral artery in rats, even when the
mAb was administered after the start of reperfusion
[41]. Furthermore, anti-HMGB1 antibody inhibited the
activation of microglia, the expression of TNF-a,a n d
iNOS. In contrast, intracerebroventricular injection of
HMGB1 increased the severity of infarction and neu-
roinflammation [41].
Additional evidence indicating that HMGB1 is asso-
ciated with ischemic brain injury comes from experi-
ments showing that downregulation of HMGB1 brain
levels with rabbit polyclonal anti-HMGB1 antibody cor-
relates with diminished infarct volumes [27].
In patients with ischemic stroke, the serum or plasma
levels of HMGB1 are dramatically higher than those in
age- and gender-matched controls [27,40]. In an
ischemic stroke animal model, the serum level of
HMGB1 increased 4 hours after ischemia [21,26], and
HMGB1 was massively released into the extracellular
space immediately after ischemic insult. HMGB1 subse-
quently induced the release of inflammatory mediators
in the post-ischemic brain [21]. Intriguingly, regarding
the relocation dynamics of HMGB1 in the neuronal
cells, HMGB1 translocated from the neuron nuclei to
the cytoplasm and subsequently was depleted from neu-
rons after one hour of MCAO [26,28], indicating that
HMGB1 is released early after ischemic injury from
neurons.
Interestingly, one most recent study found that intra-
cerebroventricular injection of recombinant human
HMGB1 (rhHMGB1) in TLR4
+/+ mice but not in
TLR4
-/- caused significantly more injury after cerebral
ischemia-reperfusion than in the control group, suggest-
ing that TLR4 contributes to HMGB1-mediated
ischemic brain injury [20]. Moreover, to determine the
potential downstream signaling of HMGB1/TLR4 in cer-
ebral ischemic injury, the ischemic-reperfusion model in
TRIF
-/- and
+/+ mice were used to evaluate the activity
and expression of TRIF pathway-related kinases [20].
There were no obvious differences in ischemic injury
between the TRIF
-/- and TRIF
+/+ mice.
In addition, the protein levels of TANK binding kinase
1 (TBK1), total IKKε, and phosphorylated-IKKε,w e r e
determined in TRIF
-/- and TRIF
+/+ mice. TRIF
-/- mice
showed no changes in TBK1, total IKKε,a n dp h o s -
phorylated-IKKε in response to ischemia-reperfusion
[20]. The results suggest that HMGB1 mediates
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dent TLR4 signaling.
However, several basic questions still need to be
answered before the broad picture of TLR involvement
in cerebral ischemic injury can emerge. So far, studies
on TLRs in ischemic brain stroke have mainly focused
on ischemic damage in TLR4- and, to a lesser extent,
TLR2-mutant mice. Although this approach has pro-
vided a first glimpse into the relevance of TLR signaling
in ischemic stroke, it has not enabled an understanding
of the role of TLR signaling in specific cell types. This
issue is of great importance because the pathology of
ischemic stroke involves many different cells, e. g., neu-
rons, astrocytes, microglial, endothelial cells, and invad-
ing immune cells. More recently, Weinstein et al [42]
present new experimental data about genomic microar-
ray analyses on primary mouse microglia derived from
either wild-type (WT) or TLR4
-/- mice following expo-
sure to either ischemia-reperfusion or control condi-
t i o n s .T h e yf o u n dt h a tt h em a rkedly disparate genomic
responses that occur in wild-type vs. TLR4-/- microglia
following exposure to hypoxic/hypoglycemic conditions.
T h e s ed a t ah a v ep r o v i d e df u r t h e rm o l e c u l a ri n s i g h t s
into both the effect of ischemia on the microglial phe-
notype and the role of microglial TLR4 in ischemia-
induced neuroinflammation and suggested that TLR4
signaling in microglia during ischemic injury play an
important role in ischemia-induced inflammatory injury.
TLRs and cerebral ischemic tolerance
A great amount of evidence from experimental studies
supports the detrimental role of innate immunity in cer-
ebral ischemic injury. As we discussed above, ablation of
TLR2, 4 and other components of TLR signaling
(HMBG1) in vivo seems to decrease infarct size, attenu-
ate inflammatory responses, and improve neurological
behavior in animal models of cerebral ischemia. Thus,
targeting TLR signaling may be a novel therapeutic
strategy for cerebral ischemic injury and other inflam-
matory diseases. For example, stimulation of some TLRs
prior to ischemia provides robust neuroprotection. TLR
ligands administered systemically induce a state of toler-
ance to subsequent ischemic injury. The stimulation of
TLRs prior to ischemia reprograms TLR signaling that
occurs following ischemic injury. Such reprogramming
leads to suppression of pro-inflammatory molecules,
while numerous anti-inflammatory mediators are
enhanced [13].
The role of TLR4 in ischemic brain tolerance
Pre-exposure of the brain to a short ischemic event can
result in subsequent resistance to severe ischemic injury
[13], a phenomenon known as preconditioning. Precon-
ditioning ischemic tolerance has been observed in
humans in clinical practice. Indeed, less severe strokes
have been described in patients with prior ipsilateral
transient ischemic attacks within a short period of time
[43].
TLR4-induced tolerance to cerebral ischemia was first
demonstrated with low-dose systemic administration of
LPS, which rendered spontaneously hypertensive rats
tolerant to ischemic brain damage induced by MCAO
[44]. Since then, LPS-induced tolerance to brain ische-
mia has been demonstrated in a mouse model of stroke
and in a porcine model of deep hypothermic circulatory
arrest [44,45].
The exact molecular mechanisms underlying ischemic
tolerance are not well understood, but requirements for
de novo protein synthesis, activation of the proinflam-
matory transcription factor NF-B, and induction of
inflammatory cytokines such as TNF-a,I L - 1 b,a n dI L - 6
have been demonstrated [46]. Suppression of the normal
inflammatory responses to ischemia is a hallmark of the
LPS-preconditioned brain. Administration of low-dose
LPS before MCAO prevented the cellular inflammatory
response in the brain and blood. Specifically, LPS pre-
conditioning suppressed neutrophil infiltration into the
brain and microglia/macrophage activation in the
ischemic brain, which was paralleled by suppressed
monocyte activation in the peripheral blood [44].
Moreover, preconditioning with LPS protects the brain
against the neurotoxic effects of TNF-a after cerebral
ischemia [47]. Mice that had been preconditioned with
LPS prior to ischemia showed a pronounced suppression
of the TNF-a pathway following stroke, with reduced
TNF-a in the serum [47]. LPS-preconditioned mice also
showed marked resistance to brain injury caused by
intracerebral administration of exogenous TNF-a after
stroke [47]. Therefore, suppression of TNF-a signaling
during ischemia confers neuroprotection after LPS
preconditioning
Interestingly, one recent study investigated whether
cerebral ischemia induced by MCAO for 2 hours dif-
fered in mice that lack functional TLR3 or TLR4 signal-
ing pathways [48]. As a result, TLR4-, but not TLR3-
knockout mice had significantly smaller infarct area and
volume 24 hours after ischemia-reperfusion compared
with wild-type mice [48]. Moreover, ischemic precondi-
tioning induced by a 6-min temporary bilateral common
carotid artery occlusion provided neuroprotection, as
shown by a reduction in infarct volume and better out-
come in mice expressing TLR4 normally but not in
TLR4-deficient mice [49]. Mice that have been precon-
ditioned displayed a pronounced reduction of TNF-a,
iNOS, and COX-2 in the brains of wild-type TLR4 mice
relative to TLR4-deficient mice [49]. Taken together,
TLR4 is involved in neuroprotection afforded by
ischemic preconditioning.
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Recently TLR9 was shown to induce tolerance to brain
ischemia [50]. Systemic administration of the immunos-
timulus CpG-ODN1826 in advance of MCAO reduced
ischemic damage up to 60% in a dose- and time-depen-
dent manner [50]. Moreover, pretreatment with CPG
protected neurons in both in vivo and in vitro models of
stroke [50]. Notably, the protection afforded by CpG
depends on TNF-a, as systemic CpG administration
acutely and significantly increases serum TNF-a,a n d
TNF-a knockout mice fail to be protected by CpG pre-
conditioning [50]. Therefore, preconditioning with a
TLR9 ligand induces neuroprotection against ischemic
injury through a mechanism that shares common ele-
ments with LPS preconditioning via TLR4. Additionally,
similarities among the known TLR signaling pathways
and their shared ability to induce TNF-a suggest that
stimulation of TLR4 and TLR9 may induce ischemic tol-
erance by similar means.
The demonstration that ischemic tolerance in the
brain occurs through TLR9, in addition to TLR4, raises
the possibility that this is a conserved feature of all
TLRs. Recognition that TLR9 is a new target for precon-
ditioning broadens the range of potential antecedent
therapies for brain ischemia. Phase II clinical trials are
already in progress with CpG-ODNs for use in adjuvant
and anticancer therapies [51]. Thus, CpG-ODNs may
offer great translational promise as a prophylactic treat-
ment against cerebral morbidity.
Mechanisms of TLR-induced neuroprotection in cerebral
ischemia
Since administration of LPS can induce ischemic toler-
ance [52], Karikó et al. developed a hypothetic model to
explain this phenomenon [52]. They hypothesized that
tolerance is dependent on the inhibition of the TLR and
cytokine signaling pathways, suppressing in this way the
inflammatory response to ischemia [53]. When an
ischemic infarction takes place, the resultant cascade of
molecular events normally involves TLR activation and
cytokine expression, which activates inflammation,
among other mechanisms. TLR and cytokine signaling
subsequently trigger other pathways that induce
immune suppression by increasing signaling inhibitors,
decoy receptors, and anti-inflammatory cytokines. Thus,
w h e na n o t h e ri s c h e m i ce v e n to c c u r st h ep r e s e n c eo f
inflammatory inhibitors reduces the inflammatory
response and subsequent secondary cell death [13,53].
In fact, the finding that TLRs are mediators of
ischemic injury provides insight into the potential
mechanisms of LPS- and CpG-induced neuroprotection
[12,13,47,54]. Cells that are tolerant of LPS are charac-
terized by their inability to generate TNF-a in response
to TLR4 activation. Upon TLR4 ligation, LPS-tolerant
cells, unlike naïve cells, do not recruit MyD88 to TLR4,
and fail to activate IRAK-1 and NF-B[ 5 5 ] .T h eT L R 4 -
NF-B signaling axis becomes decommissioned follow-
ing a primary exposure to LPS via an elaborate negative
feedback loop. This loop involves known inhibitors of
TLR signaling, including Ship-1, which prevents TLR4-
MyD88 interaction, as well as IRAK-M, a non-functional
IRAK decoy, and TRIM30a, which destabilizes the
TAK1 complex [56,57]. Thus, subsequent signaling of
TLR4 to NF-B is blocked and inflammatory cytokine
production is suppressed. Conversely, it was also found
that secondary exposure increased signaling via the
TLR4-IRF3 axis and caused enhanced IFN-b release
[54]. Thus, pretreatment with LPS causes cells to switch
their transcriptional response to TLR4 stimulation, by
enhancing the IRF3- induced cytokine IFN-b,a n ds u p -
pressing the NF-B-induced cytokine TNF-a.
Similar to LPS tolerance, priming TLR9 with CpG
induces a state of hyporesponsiveness to subsequent
challenge with CpGs [58]. Interestingly, cross tolerance
between the two receptors has also been reported, as
ligands for TLR9 induce tolerance against a subsequent
challenge with a TLR4 ligand [54,59]. CpG-pretreated
cells not only produce less TNF-a when secondarily
challenged with LPS, they also produce significantly
greater levels of IFN-b [54]. This observation suggests
that the mechanism of neuroprotection between LPS
and CpG preconditioning share common elements.
Therefore, TLR stimulation prior to stroke may repro-
gram ischemia-induced TLR activation. Specifically,
administration of LPS or CpG may activate TLR4 and
TLR9, respectively, causing a small inflammatory
response, with an initial rise in TNF-a. Cells would then
regulate their inflammatory response through expression
of negative feedback inhibitors of the TLR4-NF-Bs i g -
naling axis, when cells are subsequently exposed to
endogenous TLR ligands generated from ischemia-
injured tissue. Within this new cellular environment, sti-
mulated TLRs such as TLR4 would be unable to activate
NF-B-inducing pathways. Therefore, stroke-induced
TLR4 signaling may be blocked completely, leading to
reduced injury, and stroke-induced TLR4 signaling
would shift from NF-B induction to IRF3 induction.
Suppression of NF-B induction would be expected to
protect the brain, as mice lacking the p50 subunit of
NF-B suffer less cerebral ischemic damage than wild-
type mice [60]. Enhancement of IRF signaling would
also be expected to protect the brain, as IFN-b, a down-
stream product of IRF3 induction, has been shown to
act as an acute neuroprotectant [61,62].
Therapeutic interest in TLRs in cerebral ischemia
Since it has been established that TLR activation after
ischemia by endogenous ligands contributes to tissue
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get TLRs and their associated signaling pathways may
be useful in the treatment of cerebral ischemia. TLR
activation before ischemia has been shown to be protec-
tive [13,47,49,50,63].
Indeed, as mentioned above, several lines of evidence
suggest that TLR4 is involved in a protective effect
induced by preconditioning against ischemic brain
injury [13,49,54,63]. TLR4 is involved in ischemic pre-
conditioning where ischemia of short duration provides
resistance to subsequent challenge, thus conferring
ischemic tolerance [49]. Moreover, pretreatment with
t h eT L R 9a g o n i s tC p Gb e f o r eM C A Oa l s oc o n f e r r e d
neuroprotection [50].
Importantly, one most recent study demonstrated for
the first time that pharmacological preconditioning
against cerebrovascular ischemic injury is also possible
in a nonhuman primate (rhesus macaque) model of
stroke[64]. The model of stroke used was a minimally
invasive transient vascular occlusion, resulting in brain
damage that was primarily localized to the cortex, and
as such, represents a model with substantial clinical
relevance.
K-type cytosine-guanine-rich DNA oligonucleotides
are currently in use in human clinical trials, underscor-
ing the feasibility of this treatment in patients at risk of
cerebral ischemia [64]. Finally, another clinical study
indicates that preconditioning may occur naturally in
humans after transient ischemic attacks and mild
strokes [65]. Therefore, as ischemic preconditioning
activates endogenous signaling pathways that culminate
in protection against ischemic brain damage, drugs that
stimulate TLRs might protect against cerebral ischemic
injury.
On the other hand, it has also been proposed that
HMGB1, an exogenous ligand of TLRs, protects against
cerebral ischemic injury [30]. For example, there is evi-
dence that HMGB1 antibodies improved the outcome in
an animal model of stroke [27,41,66]. Moreover, in a
mouse model of cerebral ischemic stroke, systemic
administration of HMGB1 box A protein significantly
ameliorated ischemic brain injury [27], suggesting that
HMGB1 box A may provide a tool for therapy. How-
ever, to date, the use of HMGB1 as a pharmacologic
treatment in clinical cerebral ischemic injury has not
been explored.
Conclusions and prospective
Ischemic brain injury after cerebral ischemia results
from a complex pattern of pathophysiological events.
The contribution of inflammation to ischemic neuronal
damage is well known. TLRs are critical components of
the innate immune system that have been shown to
m e d i a t ei s c h e m i ci n j u r y .S of a r ,t h e r eh a v eo n l yb e e na
few studies that examine the role of TLRs in cerebral
ischemia, and some of them suggest that TLRs are
involved in the enhancement of cell damage following
ischemia [23,24,36]. TLR2 and TLR4 and their ligand
HMGB1 have been well documented to contribute to
ischemic brain damage [12,23,32-34,36,38].
The activation of TLR signaling leads to ischemic pre-
conditioning [12,13,34,47,50]. Recently, TLR4 and
TLR9-induced tolerance to cerebral ischemia has been
well studied. The stimulation of TLR4 and TLR9 may
induce ischemic tolerance by similar means. LPS pre-
conditioning reprograms the cellular response to stroke,
which may represent endogenous processes that protect
the brain against additional injury.
By setting the stage for improved ischemic outcome,
TLR reprogramming offers a low-risk, high-benefit
opportunity to combat neuronal injury in the event of
cerebral ischemia [64]. CpG appears to be a unique pre-
conditioning agent, coordinating both systemic and cen-
tral immune components to actively protect the body
from cerebral ischemic injury.
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